GHK (Glycine-Histidine-Lysine Tripeptide) vs Thymosin Alpha-1
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHK (Glycine-Histidine-Lysine Tripeptide)
The free tripeptide component of GHK-Cu before copper complexation. GHK naturally occurs in human plasma, saliva, and urine and promotes wound healing, collagen synthesis, and anti-inflammatory activity. While it readily chelates copper to form GHK-Cu in vivo, research distinguishes the independent effects of free GHK from the copper-complexed form on gene expression and tissue remodeling.
Full profileThymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally derived from the thymus gland. It plays a central role in regulating immune function — specifically in the maturation and differentiation of T-cells. Unlike most research peptides, Thymosin Alpha-1 has approved clinical use in multiple countries (China, Italy, and others) for hepatitis B, hepatitis C, and as an immune adjuvant in cancer patients undergoing chemotherapy. In the US it is sold as Zadaxin and used as a research compound.
Full profile| GHK (Glycine-Histidine-Lysine Tripeptide) | Thymosin Alpha-1 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | GHK tripeptide, Gly-His-Lys, copper chelating tripeptide, GHK free tripeptide | Tα1, Thymalfasin, Zadaxin |
| Evidence | Research-stage | Research-stage |
| Dosing range | 0.5mg–2mg mg, Daily or every other day (topical or SC) | 900mcg–3.2mg mg, 2–3 times per week subcutaneously |
| Administration | Subcutaneous injection, Topical (cream/serum) | Subcutaneous injection |
| Key side effects | Minimal reported side effects, Mild injection site irritation, Rare topical sensitization, No significant systemic effects at research doses | Generally very well tolerated, Mild injection site reactions (most common), Transient fatigue in initial doses, Flu-like symptoms (rare) |
| Cited sources | 2 references | 4 references |
Key differences
- Administration: GHK (Glycine-Histidine-Lysine Tripeptide) — Subcutaneous injection, Topical (cream/serum); Thymosin Alpha-1 — Subcutaneous injection.
- Frequency: GHK (Glycine-Histidine-Lysine Tripeptide) is typically Daily or every other day (topical or SC); Thymosin Alpha-1 is 2–3 times per week subcutaneously.
- Research depth: this profile cites 2 sources for GHK (Glycine-Histidine-Lysine Tripeptide) vs 4 for Thymosin Alpha-1.
How each works
GHK (Glycine-Histidine-Lysine Tripeptide)
Free GHK directly upregulates collagen, elastin, and laminin synthesis in fibroblasts through TGF-β pathway activation and metalloproteinase modulation. Loren Pickart's decades of research identified GHK as a potent tissue remodeling signal whose plasma concentrations decline with age. At physiologic concentrations, GHK resets approximately 31% of dysregulated gene expression associated with aging back toward a younger phenotype.
Thymosin Alpha-1
Extensive human clinical research documents Tα1's immune-modulating effects. It increases T-cell counts, enhances NK cell activity, and promotes Th1 cytokine balance. Multiple randomized trials have shown efficacy in treating chronic hepatitis B and C, reducing infection severity in critically ill patients, and improving outcomes in sepsis. More recent research investigates its role in long COVID immune dysregulation. It is considered one of the best-studied peptides in immunology.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.